Patents Assigned to Daiichi Asubio Pharma Co., Ltd.
-
Publication number: 20070270337Abstract: [Problems] The present invention provides a pharmaceutical composition for preventing or treating Th1-mediated immune diseases. [Means for Solving] There is obtained a pharmaceutical composition provided for prevention or treatment of Th1-mediated immune diseases, which comprises as an active ingredient a substance capable of acting on the NP receptor GC-A expressed on dendritic cells to enhance cGMP production and thereby driving T cells to differentiate into Th2-type cells by regulating cytokine production from dendritic cells.Type: ApplicationFiled: June 11, 2004Publication date: November 22, 2007Applicant: Daiichi Asubio Pharma Co., Ltd.Inventor: Toshiyuki Hori
-
Publication number: 20070155013Abstract: A novel growing method is provided for pluripotent stem cells such as ES cells. The method of the invention is a pluripotent stem cell growing method and gene transfer method in which pluripotent stem cells are cultured under conditions that maintain their undifferentiated state and pluripotency, the method being characterized by using a liquid medium and a culturing vessel having immobilized or coated on a substrate solid phase surface a molecule which is adhesive to the pluripotent stem cells in a fixed concentration, to grow the pluripotent stem cells in a dispersed state while maintaining their undifferentiated state and pluripotency, without using feeder cells, or to transfer and express a gene therein.Type: ApplicationFiled: March 23, 2005Publication date: July 5, 2007Applicants: Toshihiro Akaike, Keiichi Fukuda, Daiichi Asubio Pharma Co., Ltd.Inventors: Toshihiro Akaike, Keiichi Fukuda, Masato Nagaoka, Uichi Koshimizu
-
Patent number: 7169951Abstract: A quianazoline derivative having the formula (1): or a pharmaceutically acceptable salt thereof, which has a chymase inhibitory activity and suppresses the exacerbation of vascular permeability induced by chymase and useful as a medicament, and a pharmaceutical composition containing the same as an essential ingredient.Type: GrantFiled: March 8, 2005Date of Patent: January 30, 2007Assignee: Daiichi Asubio Pharma Co., Ltd.Inventors: Harukazu Fukami, Akiko Ito, Seiichi Imajo
-
Publication number: 20070009496Abstract: The proliferation of cardiomyocytes is induced by expressing cyclin and CDK in the cardiomyocytes, and by suppressing the function or action of a Cip/Kip family protein or inhibiting the production of a Cip/Kip family protein. Among the Cip/Kip family proteins, it is preferable to suppress the function of p27KiP1 or inhibiting the production thereof. As a recombinant vector to be used therefor, there is provided a vector comprising: (1) a cyclin gene; (2) a cyclin-dependent kinase gene; and (3) one or a plurality selected from the group consisting of a gene encoding a factor that inhibits the function or action of a Cip/Kip family protein and a nucleic acid sequence that inhibits the production of Cip/Kip family protein.Type: ApplicationFiled: November 19, 2004Publication date: January 11, 2007Applicant: Daiichi Asubio Pharma Co., Ltd.Inventors: Mimi Adachi, Keiichi Nakayama, Shigetaka Kitajima, Hiromitsu Takagi
-
Patent number: 7138489Abstract: The present invention is a method for producing a peptide or a protein in which a side chain contains a modified amino acid residue, which comprises chemically producing a peptide fragment containing an amino acid residue having a modified side chain using an weak acid-cleavable resin, producing a peptide fragment containing no amino acid residue having a modified side chain using a genetic recombination method or/and an enzymatic method, and condensing the resulting two kinds of peptide fragments and, according to the present invention, a peptide or a protein containing modification such as acylation, glycosylation and phosphorylation can be obtained effectively and at high quality.Type: GrantFiled: April 10, 2003Date of Patent: November 21, 2006Assignee: Daiichi Asubio Pharma Co., Ltd.Inventors: Yoshiharu Minamitake, Masaru Matsumoto, Tomohiro Makino
-
Patent number: 7087248Abstract: A medical component comprising a human parathyroid hormone peptide or its derivative, and acetic acid contained at a concentration less than its chemical equivalent with respect to the human parathyroid hormone peptide or to its derivative. Since in the medical component acetic acid, which is present as a salt of or attached to the peptide or its derivative, has been reduced to an amount less than chemical equivalent with respect to the human parathyroid hormone peptide or its derivative, a medical component, which is highly stable and will ensure an excellent use feeling when introduced into a pharmaceutical composition, is obtained.Type: GrantFiled: June 29, 2001Date of Patent: August 8, 2006Assignee: Daiichi Asubio Pharma Co., Ltd.Inventors: Yoshiharu Minamitake, Tetsu Ono, Koji Kawanishi, Yuji Suzuki
-
Patent number: 7067533Abstract: The present invention relates to an aminophenoxyacetamide derivative of the formula (I): wherein R1 to R4 are, independent from each other, a hydrogen atom or an optionally substituted alkyl group; E1 is —NR4—; and E2 is an oxygen atom or —NR10—; Q is the group —X—Y-Q?, wherein X and Y are connecting bonds or X is an alkylene or alkenylene group and Y is selected from a group comprising C?O, NHC(?), and C(?O)NH, and Q? is a hydrogen atom or a phenyl or pyridyl group which may be substituted; and pharmaceutically acceptable salts thereof. The present invention further relates to compositions comprising compounds of the formula (I) and methods of using said compounds for treating cerebral functional disorders and cerebral organic disorders.Type: GrantFiled: April 13, 2001Date of Patent: June 27, 2006Assignee: Daiichi Asubio Pharma Co., Ltd.Inventors: Naohiro Takemoto, Hirokazu Annoura, Norihito Murayama
-
Publication number: 20060128707Abstract: The present invention provides the compounds inhibiting PDE 7 selectively, and therefore, enhances cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is imidazotirazinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl group, R2 is methyl group; R3 is a hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; substituted or unsubstituted C1-C6 alkyl group; substituted or unsubstituted C2-C6 alkenyl group; saturated or unsaturated heterocycloalkyl group which is substituted or unsubstituted; a group: —NR5R6, —C(O)R7, —SO2R7, —OR8, —NR8COR7, —NR8S02R7; A is CR4; and B is CH.Type: ApplicationFiled: June 11, 2004Publication date: June 15, 2006Applicant: Daiichi Asubio Pharma Co., LtdInventors: Hidekazu Inoue, Hidenobu Murafuji, Yasuhiro Hayashi
-
Publication number: 20060128728Abstract: To provide the compounds inhibiting PDE 7 selectively, and therefore, enhance cellular cAMP level. Consequently, the compound is useful for treating various kinds of disease such as allergic disease, inflammatory disease or immunologic disease. The compound is pyridinylpyrazolopyrimidinone compound represented by the following formula (IA) or (IB): especially, R1 is cyclohexyl or cycloheptyl group, R2 is methyl; R3 is a group: —NR5R6 or —S(O)0-2R8; hydrogen atom; nitro group; cyano group; a halogen atom; heteroaryl group; and R4 is methoxy or ethoxy group.Type: ApplicationFiled: June 11, 2004Publication date: June 15, 2006Applicant: Daiichi Asubio Pharma Co., LtdInventors: Hidekazu Inoue, Hidenobu Murafuji, Yasuhiro Hayashi
-
Patent number: 7041820Abstract: There is provided a method by which various compounds (1) having a carboxyl group in the molecule have the carboxyl group converted to a (dioxolenon-4-yl)methyl ester at low cost, in a simple way and at high yield. The process for producing compounds of formula (3) according to the reaction scheme shown below comprises reacting carboxylic acids of formula (1) with 4-chloromethyldioxolenone compounds of formula (2) in a solvent in the presence of both a phase transfer catalyst and a metal iodide: [where Q represents an organic group, M represents a hydrogen atom, an alkali metal, an alkaline earth metal or a transition metal, R1 and R2 represent a hydrogen atom, an optionally substituted (C1-6 alkyl group or phenyl group)].Type: GrantFiled: March 29, 2002Date of Patent: May 9, 2006Assignees: Nippon Soda Co., Ltd., Daiichi Asubio Pharma Co., Ltd.Inventors: Toshiyuki Watai, Mitsuru Takase, Takahiro Sagae, Shigeo Mori, Noriaki Kawahara